How Will the Market React to Rigel Pharmaceuticals Inc (RIGL) Stock Getting a Bearish Rating

Rigel Pharmaceuticals Inc (RIGL) stock is lower by 11.98% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Rigel Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RIGL!

See Full RIGL Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With RIGL Stock Today?

Rigel Pharmaceuticals Inc (RIGL) stock is trading at $1.69 as of 1:11 PM on Tuesday, Jan 31, an increase of $0.04, or 2.42% from the previous closing price of $1.65. The stock has traded between $1.65 and $1.78 so far today. Volume today is less active than usual. So far 2,582,148 shares have traded compared to average volume of 3,464,573 shares. To see InvestorsObserver's Sentiment Score for Rigel Pharmaceuticals Inc click here.

More About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. Click Here to get the full Stock Report for Rigel Pharmaceuticals Inc stock.